Gurzu Simona, Jung J, Azamfirei L, Mezei T, Cîmpean Anca Maria, Szentirmay Z
Department of Pathology, University of Medicine and Pharmacy, Targu Mures, Romania.
Rom J Morphol Embryol. 2008;49(2):149-52.
Many clinical trials revealed that the anti-angiogenic treatment could improve prognosis in patients with metastatic colorectal carcinomas (CRC), when added to standard chemotherapy. In this paper, we tried to find out if the microvascular density (MVD) determined with CD31, CD105 was correlated with lymph node status, and if the intensity of angiogenesis was different in right versus left colon segments. We studied 187 CRC, with and without lymph node metastases, 128 from left and 59 from right colon.
In the right colon, the MVD was higher in the cases where the lymph nodes did not present metastases (pN0) but also when four or more lymph nodes were involved (pN2). In the rectum and sigma, the angiogenesis presented the highest intensity in pN0 and pN1 stage (1-3 lymph nodes with metastases), decreasing in pN2 stage. In the descendent colon segment, the MVD did not present differences between the cases with and without lymph node metastases.
Our study reveals that the most indicated cases for antiangiogenic treatment seem to be the pN0 and pN1 cases in the rectum and sigma, respectively pN0 and pN2 cases in the right colon. We tend to believe that the angiogenesis intensity in CRC is higher in early-stages of the tumoral proliferation but it is not an increasing process, having rather an oscillating character. Therefore, the angiogenesis remains an independent prognostic and predictive factor and the antiangiogenic treatment is necessary to be individualized for each patient.
多项临床试验表明,抗血管生成治疗与标准化疗联合使用时,可改善转移性结直肠癌(CRC)患者的预后。在本文中,我们试图探究用CD31、CD105测定的微血管密度(MVD)是否与淋巴结状态相关,以及左右结肠段的血管生成强度是否存在差异。我们研究了187例CRC患者,包括有和无淋巴结转移的患者,其中128例来自左半结肠,59例来自右半结肠。
在右半结肠,淋巴结无转移(pN0)的病例以及有四个或更多淋巴结受累(pN2)的病例中,MVD较高。在直肠和乙状结肠,血管生成在pN0和pN1期(1 - 3个淋巴结有转移)强度最高,在pN2期降低。在降结肠段,有无淋巴结转移的病例之间MVD无差异。
我们的研究表明,抗血管生成治疗最适用的病例似乎分别是直肠和乙状结肠的pN0和pN1病例,以及右半结肠的pN0和pN2病例。我们倾向于认为,CRC中的血管生成强度在肿瘤增殖早期较高,但并非呈递增过程,而是具有振荡特征。因此,血管生成仍然是一个独立的预后和预测因素,抗血管生成治疗需要针对每个患者进行个体化。